<DOC>
	<DOC>NCT02465632</DOC>
	<brief_summary>This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1%/ Benzoyl peroxide 5% topical gel (Glenmark Generics, Ltd), and the marketed product BenzaClin® Topical Gel, Clindamycin 1%/ Benzoyl peroxide 5% (Valeant Pharmaceuticals, US) in the treatment of acne vulgaris.</brief_summary>
	<brief_title>To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>1. Male or nonpregnant, nonlactating female, ≥12 and ≤40 years of age with a clinical diagnosis of acne vulgaris. 2. Have facial acne with: ≥20 facial inflammatory lesions (papules and pustules) and ≥25 noninflammatory lesions (open and closed comedones), and ≤2 nodulocystic lesions (nodules and cysts) and have an IGA score of 2, 3 or 4. 1. Subject has more than 2 facial nodular lesions; any nodules present will be documented but not included in the inflammatory lesion count for analysis. 2. Subject has active cystic acne. 3. Subject has acne conglobata. 4. Subjects with excessive facial hair such as beards, sideburns, moustaches, etc. that would interfere with the diagnosis or assessment of acne.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>